GlassScriptPhysician profile
Daniel L Mayer
NPI 1245273135
$3,962.55
in general payments reported to CMS, 2019-2025
31 companies · $713 in 2025
The $713 reported for 2025 was more than what a typical Pediatric Allergy/Immunology provider received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $128 · 2021: $380 · 2022: $666 · 2023: $836 · 2024: $611 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,142 · Education: $17.71.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,142.49 |
| Education | $17.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $727.67 | 2019-2025 | Nucala, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $367.13 | 2020-2025 | Airsupra, Tezspire, Fasenra |
| Regeneron Healthcare Solutions, INC. | $358.92 | 2019-2025 | Dupixent |
| Salvin Dental Specialties, INC. | $274.38 | 2021 | |
| Kaleo, INC. | $232.10 | 2019-2024 | Auvi-Q |
| Optinose US, INC. | $230.72 | 2019-2025 | |
| Csl Behring | $164.91 | 2024-2025 | Hizentra |
| Shire North American Group INC | $161.01 | 2019 | |
| Pfizer INC. | $142.65 | 2019-2025 | |
| Aytu Biopharma, INC. | $136.07 | 2022-2025 | Karbinal |
| Takeda Pharmaceuticals U.S.A., INC. | $120.59 | 2022-2025 | Cuvitru, Eohilia |
| Novartis Pharmaceuticals Corporation | $113.46 | 2019-2025 | |
| Incyte Corporation | $112.39 | 2022-2025 | Opzelura |
| Genzyme Corporation | $110.66 | 2019-2024 | |
| Leo Pharma INC. | $106.07 | 2022-2023 | Adbry |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.02 | 2019-2022 | |
| Genentech USA, INC. | $75.03 | 2023-2025 | Xolair |
| Amgen INC. | $65.26 | 2022 | |
| Abbvie INC. | $54.50 | 2023 | |
| Hikma Pharmaceuticals USA | $43.50 | 2023 | Ryaltris |
| Grifols USA, LLC | $43.49 | 2023-2025 | Xembify |
| Teva Pharmaceuticals USA, INC. | $39.88 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $32.35 | 2025 | Neffy |
| Alk-Abello, INC | $26.80 | 2021-2022 | |
| Lilly USA, LLC | $24.51 | 2025 | Ebglyss |
| Blueprint Medicines Corporation | $20.67 | 2023 | Ayvakit |
| Biocryst US Sales Co., LLC | $20.51 | 2024 | Orladeyo |
| Phadia US INC. | $18.93 | 2024 | Immunocap |
| Pharming Healthcare, INC. | $18.15 | 2019 | |
| Covis Pharma Gmbh | $16.36 | 2019 | |
| Circassia INC. | $10.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.